Prostate Cancer

Enzalutamide plus androgen deprivation therapy produced a statistically significant improvement in time to prostate-specific antigen progression compared with ADT and placebo in men with metastatic hormone-sensitive prostate cancer, meeting the primary end point of the phase 3 China ARCHES study.

Precision medicine and personalized medicine are 2 concepts that have pushed their way to the forefront of oncology practice.

Andrei H. Iagaru, MD, discusses key points from his presentation on the use of novel vs conventional imaging to manage metastatic hormone-sensitive prostate cancer.

Patients with metastatic castration-resistant prostate cancer have traditionally been burdened by a poor outlook; however, emerging therapeutic targets and novel agents directed at them are poised to affect change in this population.

Jeremie Calais, MD, MSc, discusses the role of prostate-specific membrane antigen-PET imaging in metastatic-castrate resistant prostate cancer, and touches on the importance of integrating PSMA-PET imaging into community settings for clinical practice.

Tanya Dorff, MD, discusses key data supporting the use of intensified triplet regimens in metastatic hormone-sensitive prostate cancer, and remaining questions regarding the role of chemotherapy agents in these combinations.

Matthew Rettig, MD, discusses the evolution of triplet therapy within the landscape of metastatic hormone-sensitive prostate cancer, as well as the importance of considering key prognostic factors when utilizing this approach.

Tian Zhang, MD, MHS, discusses key phase 3 trials evaluating PARP inhibitors in the treatment of metastatic castration-resistance prostate cancer.

Maha H. Hussain, MD, FASCO, FACP, discusses key efficacy and safety data from a secondary analysis of the phase 3 ARASENS trial in metastatic hormone-sensitive prostate cancer.

Expert oncologist Matthew Smith, MD, PhD, reviews efficacy and safety data from the phase 3 ARASENS study combining darolutamide with ADT and docetaxel in patients with metastatic hormone-sensitive prostate cancer.

Bertrand Tombal, MD, PhD, discusses the rationale for conducting a phase 2 study of darolutamide monotherapy in newly diagnosed metastatic hormone-sensitive prostate cancer.

Boris A. Hadaschik, MD, discusses results from a post-hoc analysis of subsequent therapy for patients with nonmetastatic castration-resistant prostate cancer who progressed following treatment with apalutamide.

Eleni Efstathiou, MD, PhD, expands on the updated interim data from the MAGNITUDE trial and sheds light on the utility of PARP inhibitor combinatorial strategies in patients with mCRPC and HRR gene alterations.

Chandler Park, MD, MSc, FACP, discusses how the emerging field of radiotheranostics and increasing utilization of biomarker testing will improve the treatment of patients with metastatic hormone-sensitive prostate cancer.

Daniel P. Petrylak, MD, discusses efficacy and safety data from the phase 3 KEYNOTE-921 trial of pembrolizumab and docetaxel in metastatic castrate-resistant prostate cancer.

Medical oncologist Tian Zhang, MD, outlines the remaining unmet needs and knowledge gaps surrounding imaging of prostate cancer.

Five expert panelists in prostate cancer consider how recent advances in imaging, particularly PSMA-PET, have impacted the field, and highlight guidelines that may aid clinicians in selecting amongst the available imaging modalities.

Neil H. Bander, MD, discusses preliminary results from a phase 1/2 study of pembrolizumab in combination with an androgen-receptor signaling inhibitor and alpha-PSMA-targeted radionuclide therapy in mCRPC.

Phillip J. Koo, MD, discusses ongoing areas of technological and therapeutic advancements within the prostate cancer landscape.

Neal Shore, MD, FACS, US discusses the continued evaluation of darolutamide in patients with non-metastatic castration-resistant prostate cancer.

A new drug application has been submitted to the FDA seeking the approval of niraparib in combination with abiraterone acetate, in the form of a dual-action tablet, and prednisone, for the first-line treatment of patients with metastatic castration-resistant prostate cancer harboring BRCA mutations.

Paul L. Nguyen, MD, discusses primary findings from the phase 2 FORMULA-509 trial in prostate cancer.

The addition of pembrolizumab to standard therapies failed to improve survival outcomes in patients with metastatic castration-resistant prostate cancer in the KEYNOTE-641 trial and patients with EGFR-mutated non–small cell lung cancer in the KEYNOTE-789 trial.

Michael S. Leapman, MD, MHS, discusses key factors that influence patient experiences with biopsy-based genomic testing during active surveillance for prostate cancer, and how to best address them in clinical practice.

Matthew Rettig, MD, discusses emerging treatment options for patients with stage IV metastatic prostate cancer and highlights key data from clinical trials in the space.

Andrei H. Iagaru, MD, discusses molecular imaging and the use of prostate-specific membrane antigen PET scans in prostate cancer and highlights other key presentations from the 2023 Prost8 Cancer Conference.

Tian Zhang, MD, MHS, discusses findings with single-agent PARP inhibitors within homologous recombination repair–deficient metastatic castration-resistant prostate cancer and describes how these advances pave the way for combining PARP inhibitors with hormonal therapies.

Phillip J. Koo, MD, highlights insights garnered from prostate cancer experts on topics such as radioligands and modern radiopharmaceuticals, which, along with artificial intelligence, have the potential to revolutionize the field.

Tian Zhang, MD, MHS, discusses the use of PARP inhibitor–based combinations in patients with metastatic castration-resistant prostate cancer.

Michael S. Cookson, MD, MMHC, explains how discrepancies in defining biochemical recurrence are sparking a conversation about creating more consistent definitions that could allow for more widely applicable standards of care in prostate cancer .